A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-Cell Acute Lymphoblastic Leukemia (ALL)

Patients must have a prior morphologic diagnosis of ALL with FAB class L1-L2, and be either refractory to a standard induction regimen (defined as any program of treatment that includes at least vincristine and prednisone), or have relapsed following successful prior induction therapy. Patients who have received any number of inductions or achieved any number of remissions are eligible. Blood or BM lymphocytes immunophenotype must reveal a preponderance of non T-cells as determined by appropriate marker studies (CD19+). Patients with extramedullary disease in the absence of bone marrow or blood involvement are also eligible, provided histologic documentation of their diagnosis is obtained from a tissue sample. Patients must be >16 yrs., Zubrod PS 0-3, no CNS involvement, and adequate renal and liver function. Patients must not have neuropathy >/= Grade 2 at the time of registration.